Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Status: Enrolling
Updated:  12/31/1969
Rambam Medical Center
mi
from
Haifa,
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Status: Enrolling
Updated: 12/31/1969
Rambam Medical Center
mi
from
Haifa,
Click here to add this to my saved trials
A Model for Genetic Susceptibility: Melanoma
A Model for Genetic Susceptibility: Melanoma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Model for Genetic Susceptibility: Melanoma
A Model for Genetic Susceptibility: Melanoma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection
Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection
Status: Enrolling
Updated:  12/31/1969
Yale School of Public Health
mi
from
New Haven, CT
Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection
Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection
Status: Enrolling
Updated: 12/31/1969
Yale School of Public Health
mi
from
New Haven, CT
Click here to add this to my saved trials
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital, Anschutz Cancer Pavilion
mi
from
Aurora, CO
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital, Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated:  12/31/1969
Baylor University Medical Center
mi
from
Dallas, TX
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated: 12/31/1969
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated:  12/31/1969
Blacktown Hospital
mi
from
Blacktown,
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated: 12/31/1969
Blacktown Hospital
mi
from
Blacktown,
Click here to add this to my saved trials
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated:  12/31/1969
HonorHealth Research Institute - Bisgrove
mi
from
Scottsdale, AZ
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status: Enrolling
Updated: 12/31/1969
HonorHealth Research Institute - Bisgrove
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Central Jersey Division
mi
from
East Brunswick, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Central Jersey Division
mi
from
East Brunswick, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Freehold Division
mi
from
Freehold, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Freehold Division
mi
from
Freehold, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
Hackensack Meridian Health System
mi
from
Hackensack, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
Hackensack Meridian Health System
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Hackettstown Division
mi
from
Hackettstown, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Hackettstown Division
mi
from
Hackettstown, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Howell Division
mi
from
Howell, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Howell Division
mi
from
Howell, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Little Silver Division
mi
from
Little Silver, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Little Silver Division
mi
from
Little Silver, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Marmora Division
mi
from
Marmora, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Marmora Division
mi
from
Marmora, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Mount Holly Division
mi
from
Mount Holly, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Mount Holly Division
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Pompton Plains Division
mi
from
Pompton Plains, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Pompton Plains Division
mi
from
Pompton Plains, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Sparta Division
mi
from
Sparta, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Sparta Division
mi
from
Sparta, NJ
Click here to add this to my saved trials
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Status: Enrolling
Updated:  12/31/1969
Alliance for Clinical Trials in Oncology
mi
from
Boston, MA
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Status: Enrolling
Updated: 12/31/1969
Alliance for Clinical Trials in Oncology
mi
from
Boston, MA
Click here to add this to my saved trials
Translation of District Sun Safe Policies to Schools
Translation of District Sun Safe Policies to Schools
Status: Enrolling
Updated:  12/31/1969
Claremont Graduate University
mi
from
Claremont, CA
Translation of District Sun Safe Policies to Schools
Translation of District Sun Safe Policies to Schools
Status: Enrolling
Updated: 12/31/1969
Claremont Graduate University
mi
from
Claremont, CA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Keck Medical Center of University of Southern California
mi
from
Los Angeles, CA
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Keck Medical Center of University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Palo Alto, CA
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Aurora, CO
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University Clinical Trials Unit
mi
from
Baltimore, MD
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University Clinical Trials Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Allegheny Endocrinology Associates
mi
from
Pittsburgh, PA
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Allegheny Endocrinology Associates
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated:  12/31/1969
St Vincent's Private Hospital-NSW
mi
from
Darlinghurst,
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Status: Enrolling
Updated: 12/31/1969
St Vincent's Private Hospital-NSW
mi
from
Darlinghurst,
Click here to add this to my saved trials
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated:  12/31/1969
Trius Study Site #011
mi
from
Dothan, AL
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated: 12/31/1969
Trius Study Site #011
mi
from
Dothan, AL
Click here to add this to my saved trials
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated:  12/31/1969
Trius Study site #001
mi
from
Chula Vista, CA
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated: 12/31/1969
Trius Study site #001
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated:  12/31/1969
Trius Study Site #009
mi
from
Long Beach, CA
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated: 12/31/1969
Trius Study Site #009
mi
from
Long Beach, CA
Click here to add this to my saved trials
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated:  12/31/1969
Trius Study site #002
mi
from
Oceanside, CA
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated: 12/31/1969
Trius Study site #002
mi
from
Oceanside, CA
Click here to add this to my saved trials
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated:  12/31/1969
Trius Study site #010
mi
from
Pasadena, CA
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Status: Enrolling
Updated: 12/31/1969
Trius Study site #010
mi
from
Pasadena, CA
Click here to add this to my saved trials